Wells Fargo & Company Keros Therapeutics, Inc. Transaction History

Wells Fargo & Company

$507 Billion
Q3 2025

A detailed history of Wells Fargo & Company transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 25,890 shares of KROS stock, worth $446,861. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,890

Previous 21,945 17.98%

Holding current value

$446,861

Previous $292,000 40.07%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$13.34 - $16.05 $52,626 - $63,317	3,945 Added 17.98%	25,890 $409,000
Q2 2025 Aug 14, 2025	BUY	$9.55 - $15.11 $49,344 - $78,073	5,167 Added 30.8%	21,945 $292,000
Q1 2025 May 13, 2025	BUY	$10.15 - $16.1 $15,935 - $25,277	1,570 Added 10.32%	16,778 $170,000
Q4 2024 Feb 12, 2025	BUY	$15.64 - $70.0 $64,952 - $290,710	4,153 Added 37.57%	15,208 $240,000
Q3 2024 Nov 13, 2024	SELL	$41.68 - $58.07 $19,339 - $26,944	-464 Reduced 4.03%	11,055 $641,000

Q2 2024 Aug 13, 2024	BUY	$44.58 - $66.89 $98,521 - $147,826	2,210 Added 23.74%	11,519 $526,000
Q1 2024 May 10, 2024	BUY	$41.26 - $70.48 $138,757 - $237,024	3,363 Added 56.56%	9,309 $616,000
Q4 2023 Feb 09, 2024	SELL	$27.12 - $41.05 $251,999 - $381,436	-9,292 Reduced 60.98%	5,946 $236,000
Q3 2023 Nov 13, 2023	SELL	$31.57 - $43.02 $192,103 - $261,776	-6,085 Reduced 28.54%	15,238 $485,000
Q2 2023 Aug 15, 2023	BUY	$37.26 - $51.01 $261,416 - $357,886	7,016 Added 49.04%	21,323 $856,000
Q1 2023 May 12, 2023	BUY	$41.44 - $59.32 $590,934 - $845,903	14,260 Added 30340.43%	14,307 $610,000
Q4 2022 Feb 13, 2023	SELL	$39.45 - $51.77 $24,380 - $31,993	-618 Reduced 92.93%	47 $2,000
Q3 2022 Nov 14, 2022	SELL	$27.8 - $40.12 $97,633 - $140,901	-3,512 Reduced 84.08%	665 $25,000
Q2 2022 Aug 12, 2022	BUY	$26.03 - $67.04 $70,124 - $180,605	2,694 Added 181.66%	4,177 $115,000
Q1 2022 May 16, 2022	SELL	$42.12 - $59.36 $225,384 - $317,635	-5,351 Reduced 78.3%	1,483 $81,000
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $252,405 - $429,601	6,831 Added 227700.0%	6,834 $400,000
Q3 2021 Nov 15, 2021	SELL	$29.27 - $43.71 $175 - $262	-6 Reduced 66.67%	3 $0
Q2 2021 Aug 16, 2021	SELL	$42.4 - $70.11 $17,892 - $29,586	-422 Reduced 97.91%	9 $0
Q1 2021 May 13, 2021	SELL	$54.0 - $75.28 $1.03 Million - $1.44 Million	-19,083 Reduced 97.79%	431 $27,000
Q4 2020 Feb 09, 2021	BUY	$36.0 - $82.74 $251,712 - $578,518	6,992 Added 55.84%	19,514 $1.38 Million
Q3 2020 Nov 05, 2020	BUY	$27.04 - $62.21 $13,492 - $31,042	499 Added 4.15%	12,522 $483,000
Q2 2020 Aug 13, 2020	BUY	$20.08 - $40.39 $241,421 - $485,608	12,023 New	12,023 $451,000

Others Institutions Holding KROS

# of Institutions

169

Shares Held

35.4M

Call Options Held

574K

Put Options Held

325K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $445M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Keros Therapeutics, Inc. Transaction History